Kornitzer Capital Management Inc. KS Buys 15,000 Shares of GRIFOLS S A/S (NASDAQ:GRFS)

Kornitzer Capital Management Inc. KS increased its stake in GRIFOLS S A/S (NASDAQ:GRFS) by 5.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 278,500 shares of the biotechnology company’s stock after purchasing an additional 15,000 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in GRIFOLS S A/S were worth $5,581,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Atria Investments LLC raised its holdings in GRIFOLS S A/S by 89.2% during the second quarter. Atria Investments LLC now owns 38,413 shares of the biotechnology company’s stock valued at $1,492,000 after acquiring an additional 18,114 shares during the period. JPMorgan Chase & Co. raised its holdings in GRIFOLS S A/S by 3.7% during the second quarter. JPMorgan Chase & Co. now owns 1,615,633 shares of the biotechnology company’s stock valued at $33,233,000 after acquiring an additional 57,155 shares during the period. Wells Fargo & Company MN raised its holdings in GRIFOLS S A/S by 2.0% during the second quarter. Wells Fargo & Company MN now owns 226,399 shares of the biotechnology company’s stock valued at $4,777,000 after acquiring an additional 4,414 shares during the period. Cardinal Capital Management raised its holdings in GRIFOLS S A/S by 1.1% during the third quarter. Cardinal Capital Management now owns 53,914 shares of the biotechnology company’s stock valued at $1,080,000 after acquiring an additional 602 shares during the period. Finally, Quadrant Capital Group LLC raised its holdings in GRIFOLS S A/S by 24.8% during the second quarter. Quadrant Capital Group LLC now owns 20,324 shares of the biotechnology company’s stock valued at $422,000 after acquiring an additional 4,033 shares during the period. 18.00% of the stock is currently owned by institutional investors.

Shares of GRIFOLS S A/S stock traded up $0.12 during trading on Friday, reaching $21.52. 834,900 shares of the stock traded hands, compared to its average volume of 1,166,989. The business has a fifty day simple moving average of $20.70 and a two-hundred day simple moving average of $20.44. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.62 and a quick ratio of 0.96. GRIFOLS S A/S has a 52-week low of $17.42 and a 52-week high of $23.03. The company has a market capitalization of $14.78 billion, a price-to-earnings ratio of 18.39, a P/E/G ratio of 1.37 and a beta of 1.08.

GRFS has been the topic of a number of recent analyst reports. Berenberg Bank raised GRIFOLS S A/S to a “buy” rating in a report on Wednesday, October 30th. Zacks Investment Research lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, October 29th. Santander upgraded GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research report on Monday, October 28th. BidaskClub upgraded GRIFOLS S A/S from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 16th. Finally, ValuEngine upgraded GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $20.75.

GRIFOLS S A/S Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Featured Story: Google Finance

Institutional Ownership by Quarter for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply